Bank of America Boosts Aardvark Therapeutics (NASDAQ:AARD) Price Target to $26.00

Aardvark Therapeutics (NASDAQ:AARD) had its price target upped by equities researchers at Bank of America from $22.00 to $26.00 in a research note issued to investors on Thursday, Marketbeat.com reports. The brokerage presently has a “buy” rating on the stock. Bank of America‘s price target would suggest a potential upside of 235.92% from the company’s current price.

A number of other research analysts have also weighed in on AARD. Royal Bank of Canada assumed coverage on Aardvark Therapeutics in a report on Monday, March 10th. They set an “outperform” rating and a $21.00 price objective on the stock. Morgan Stanley began coverage on shares of Aardvark Therapeutics in a research note on Monday, March 10th. They set an “overweight” rating and a $29.00 price target on the stock. Finally, Cantor Fitzgerald initiated coverage on shares of Aardvark Therapeutics in a research note on Monday, March 10th. They issued an “overweight” rating and a $50.00 price objective for the company.

Aardvark Therapeutics Stock Down 13.0 %

Shares of AARD opened at $7.74 on Thursday. Aardvark Therapeutics has a twelve month low of $7.74 and a twelve month high of $19.58.

Insider Buying and Selling at Aardvark Therapeutics

In other Aardvark Therapeutics news, CFO Nelson Sun purchased 10,000 shares of Aardvark Therapeutics stock in a transaction on Friday, February 14th. The shares were bought at an average price of $16.00 per share, with a total value of $160,000.00. Following the completion of the acquisition, the chief financial officer now directly owns 99,484 shares of the company’s stock, valued at approximately $1,591,744. This trade represents a 11.18 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Tien-Li Lee acquired 16,542 shares of the company’s stock in a transaction dated Friday, February 14th. The shares were acquired at an average cost of $16.00 per share, with a total value of $264,672.00. Following the completion of the purchase, the chief executive officer now owns 1,496,175 shares in the company, valued at approximately $23,938,800. This represents a 1.12 % increase in their ownership of the stock. The disclosure for this purchase can be found here.

About Aardvark Therapeutics

We are a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. We target biological pathways associated with alleviating hunger that we believe have the potential to deliver transformative outcomes for patients.